Oral glucosamine modulates the response of the liver and lymphocytes of the mesenteric lymph nodes in a papain-induced model of joint damage and repair

Osteoarthritis and Cartilage

Volumn 17, Issue 8, 2009, Pages 1014-1021

  Panicker, S ^a   Borgia, J ^a   Fhied, C ^a   Mikecz, K ^a   Oegema, T R ^a  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Cartilage; Cytokines; Glucosamine; Joint; Liver; Mesenteric lymph nodes; Papain; Serum

Indexed keywords

GAMMA INTERFERON; GLUCOSAMINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 12; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 6; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; PAPAIN; PROTEOGLYCAN; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTHROPATHY; ARTICLE; CARBOHYDRATE SYNTHESIS; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG MECHANISM; FEMALE; IMMUNOASSAY; LIVER; LYMPHOCYTE; LYMPHOCYTE ACTIVATION; MESENTERY LYMPH NODE; MOUSE; NONHUMAN; PATELLA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION;

ANIMALS; ARTHRITIS, EXPERIMENTAL; CARTILAGE, ARTICULAR; FEMALE; GLUCOSAMINE; KNEE JOINT; LIVER; LYMPHOCYTES; MICE; MICE, INBRED C57BL; OSTEOARTHRITIS;

EID: 67650432179     PISSN: 10634584     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.joca.2009.01.011     Document Type: Article

References (40)

1. CDC. Prevalence of disabilities and associated health conditions among adults - United States. MMWR 2001 50 (1999) 120-125
2. Hopman W.M., Towheed T.E., Gao Y., Berger C., Joseph L., Vik S.A., et al. Prevalence of and factors associated with glucosamine use in Canada. Osteoarthritis Cartilage 14 (2006) 1288-1293
3. Block G., Jensen C.D., Norkus E.P., Dalvi T.B., Wong L.G., McManus J.F., et al. Usage patterns, health, and nutritional status of long-term multiple dietary supplement users: a cross-sectional study. Nutr J 24 6 (2007) 30
4. Sawitzke A.D., Shi H., Finco M.F., Dunlop D.D., Bingham III C.O., Harris C.L., et al. The effect of glucosamine and/or chondroitin sulfate on the progression of knee osteoarthritis: a report from the glucosamine/chondroitin arthritis intervention trial. Arthritis Rheum 58 (2008) 3183-3191
5. Reginster J.Y., Deroisy R., Rovati L.C., Lee R.L., Lejeune E., Bruyere O., et al. Long-term effects of glucosamine sulphate on osteoarthritis progression: a randomised, placebo-controlled clinical trial. Lancet 357 (2001) 251-256
6. Pavelka K., Gatterova J., Olejarova M., Machacek S., Giacovelli G., and Rovati L.C. Glucosamine sulfate use and delay of progression of knee osteoarthritis: a 3-year, randomized, placebo-controlled, double-blind study. Arch Intern Med 162 (2002) 2113-2123
7. Bruyere O., Pavelka K., Rovati L.C., Gatterová J., Giacovelli G., Olejarová M., et al. Total joint replacement after glucosamine sulphate treatment in knee osteoarthritis: results of a mean 8-year observation of patients from two previous 3-year, randomised, placebo-controlled trials. Osteoarthritis Cartilage 16 (2008) 254-260
8. Rozendaal R.M., Uitterlinden E.J., van Osch G.J., Garling E.H., Willemsen S.P., Ginai A.Z., et al. Effect of glucosamine sulphate on joint space narrowing, pain and function in patients with hip osteoarthritis; subgroup analyses of a randomized controlled trial. Osteoarthritis Cartilage 17 (2009) 427-432
9. Vlad S.C., LaValley M.P., McAlindon T.E., and Felson D.T. Glucosamine for pain in osteoarthritis: why do trial results differ?. Arthritis Rheum 56 (2007) 2267-2277
10. Reginster J.Y. The efficacy of glucosamine sulfate in osteoarthritis: financial and nonfinancial conflict of interest. Arthritis Rheum 56 (2007) 2105-2110
11. Moore A., Derry S., and McQuay H. Differing results of trials of glucosamine for pain in arthritis: comment on the article by VLAD et al. Arthritis Rheum 58 (2008) 332-333
12. Oegema T., Deloria L., Sandy J., and Hart D. Effect of oral glucosamine on cartilage and meniscus in normal and chymopapain-injected knees of young rabbits. Arthritis Rheum 46 (2002) 2495-2503
13. Tiraloche G., Girard C., Chouinard L., Sampalis J., Moquin L., Ionescu, et al. Effect of oral glucosamine on cartilage degradation in a rabbit model of osteoarthritis. Arthritis Rheum 52 (2005) 1118-1128
14. Setnikar I., Pacini M., and Revil L. Antiarthritic effects of GlcN sulfate studied in animal models. Arzneim-Forsch/Drug Res 41 (1991) 542-545
15. Mroz P.J., and Silbert J.E. Use of 3H-glucosamine and 35S-sulfate with cultured human chondrocytes to determine the effect of glucosamine concentration on formation of chondroitin sulfate. Arthritis Rheum 50 (2004) 3574-3579
16. Byron C.R., Stewart M.C., Stewart A.A., and Pondenis H.C. Effects of clinically relevant concentrations of glucosamine on equine chondrocytes and synoviocytes in vitro. Am J Vet Res 69 (2008) 1129-1134
17. Gouze J.N., Gouze E., Popp M.P., Bush M.L., Dacanay E.A., Kay J.D., et al. Exogogenous glucosamine globally protects chondrocytes from the arthritogenic effects of IL-1beta. Arthritis Res Ther 8 (2006) R173
18. Valvason C., Musacchio E., Pozzuoli A., Ramonda R., Aldegheri R., and Punzi L. Influence of glucosamine sulphate on oxidative stress in human osteoarthritic chondrocytes: effects on HO-1, p22(Phox) and iNOS expression. Rheumatology (Oxford) 47 (2008) 31-35
19. Varghese S., Theprungsirikul P., Sahani S., Hwang N., Yarema K., and Elisseeff J. Glucosamine modulates chondrocyte proliferation, matrix synthesis, and gene expression. Osteoarthritis Cartilage 15 (2007) 59-68
20. Meulyzer M., Vachon P., Beaudry F., Vinardell T., Richard H., Beauchamp G., et al. Comparison of pharmacokinetics of glucosamine and synovial fluid levels following administration of glucosamine sulphate or glucosamine hydrochloride. Osteoarthritis Cartilage 16 (2008) 973-979
21. Persiani S., Rotini R., Trisolino G., Rovati L.C., Locatelli M., Paganini D., et al. Synovial and plasma glucosamine concentrations in osteoarthritic patients following oral crystalline glucosamine sulphate at therapeutic dose. Osteoarthritis Cartilage 15 (2007) 764-772
22. Bigee B.A., Blinn C.M., McAlindon T.E., Nuite M., and Silbert J.E. Low levels of human serum glucosamine after ingestion of glucosamine sulphate relative to capability for peripheral effectiveness. Ann Rheum Dis 65 (2006) 222-226
23. Laverty S., Sandy J., Celeste C., Vachon P., Marier J., and Plaas A. Synovial fluid levels and serum pharmacokinetic in a large animal model following treatment with oral glucosamine at clinically relevant doses. Arthritis Rheum 52 (2005) 181-191
24. Meulyzer M., Vachon P., Beaudry F., Vinardell T., Richard H., Beauchamp G., et al. Joint inflammation increases glucosamine levels attained in synovial fluid following oral administration of glucosamine hydrochloride. Osteoarthritis Cartilage 17 (2008) 228-234
25. Gouze J.N., Bianchi A., Bécuwe P., Dauça M., Netter P., Magdalou J., et al. Glucosamine modulates IL-1-induced activation of rat chondrocytes at a receptor level, and by inhibiting the NF-κB pathway. FEBS Lett 510 (2002) 166-170
26. van der Kraan P.M., Vitters E.L., van de Putte L.B., and van den Berg W.B. Development of osteoarthritic lesions in mice by "metabolic" and "mechanical" alterations in the knee joints. Am J Pathol 135 (1989) 1001-1014
27. Király K., Lapveteläinen T., Arokoski J., Törrönen K., Módis L., Kiviranta I., et al. Application of selected cationic dyes for the semiquantitative estimation of glycosaminoglycans in histological sections of articular cartilage by microspectrophotometry. Histochem J 28 (1996) 577-590
28. Martin I., Jakob M., Schafer D., Spagnoli D.W., and Heberer H. Quantitative analysis of gene expression in human articular cartilage from normal and osteoarthritic joints. Osteoarthritis Cartilage 9 (2001) 112-118
29. Stoop R., Gal I., Glant T.T., McNeish J.D., and Mikecz K. Trafficking of CD44-deficient murine lymphocytes under normal and inflammatory conditions. Eur J Immunol 32 (2002) 2532-2542
30. Aigner T., Soeder S., and Haag J. IL-1b and BMPs - interactive players of cartilage matrix degradation and regeneration. Eur Cell Mater 12 (2006) 49-56
31. Shikhman A.R., Kuhn K., Alaaeddine N., and Lotz M. N-acetylglucosamine prevents IL-1β-mediated activation of human chondrocytes. J Immunol 166 (2001) 5155-5160
32. Chan P.S., Caron J.P., and Orth M.W. Effects of glucosamine and chondroitin sulfate on bovine cartilage explants under long-term culture conditions. Am J Vet Res 68 (2007) 709-715
33. Brennan F.M., Maini R.N., and Feldmann M. Role of pro-inflammatory cytokines in rheumatoid arthritis. Springer Semin Immunopathol 20 (1998) 133-147
34. Zhang G.X., Yu S., Gran B., and Rostami A. Glucosamine abrogates the acute phase of experimental autoimmune encephalomyelitis by induction of Th2 response. J Immunol 175 (2005) 7202-7208
35. Hua J., Suguro S., Hirano S., Sakamoto K., and Nagaoka I. Preventive actions of a high dose of glucosamine on adjuvant arthritis in rats. Inflamm Res 54 (2005) 127-132
36. Ma L., Rudert W.A., Harnaha J., Wright M., Machen J., Lakomy R., et al. Immunosuppressive effects of glucosamine. J Biol Chem 277 (2002) 39343-39349
37. Wells L., Whelan S.A., and Hart G.W. O-GlcNAc: a regulatory post-translational modification. Biochem Biophys Res Commun 302 (2003) 435-441
38. Zachara N.E., and Hart G.W. Cell signaling, the essential role of O-GlcNAc!. Biochim Biophys Acta 1761 (2006) 599-617
39. Comer F., and Hart G. Reciprocity between O-GlcNAc and O-phosphate on the carboxyl terminal domain of RNA polymerase II. Biochemistry 40 (2001) 7845-7852
40. Dodge G., and Jimenez S. Glucosamine sulfate modulates the levels of aggrecan and matrix metalloproteinase-3 synthesized by cultured human osteoarthritis articular chondrocytes. Osteoarthritis Cartilage 11 (2003) 424-432